Effect of glucose or fat challenge on aspirin resistance in diabetes

Hussein N. Yassine; Grace Davis-Gorman; Craig S. Stump; Stephen S. Thomson; Justin Peterson; Paul F. McDonagh

doi:10.1155/2010/820876

Effect of glucose or fat challenge on aspirin resistance in diabetes

Hussein N. Yassine, Grace Davis-Gorman, Craig S. Stump, Stephen S. Thomson, Justin Peterson, Paul F. McDonagh

Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P =.01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P =.1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P <.05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P <.05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.

Original language	English (US)
Article number	820876
Journal	International Journal of Endocrinology
Volume	2010
DOIs	https://doi.org/10.1155/2010/820876
State	Published - 2010

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Endocrine and Autonomic Systems

Access to Document

10.1155/2010/820876

Cite this

@article{f92160ce5179482f801077b77c2c7a4e,

title = "Effect of glucose or fat challenge on aspirin resistance in diabetes",

abstract = "Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P =.01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P =.1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P <.05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P <.05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.",

author = "Yassine, {Hussein N.} and Grace Davis-Gorman and Stump, {Craig S.} and Thomson, {Stephen S.} and Justin Peterson and McDonagh, {Paul F.}",

year = "2010",

doi = "10.1155/2010/820876",

language = "English (US)",

volume = "2010",

journal = "International Journal of Endocrinology",

issn = "1687-8337",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Effect of glucose or fat challenge on aspirin resistance in diabetes

AU - Yassine, Hussein N.

AU - Davis-Gorman, Grace

AU - Stump, Craig S.

AU - Thomson, Stephen S.

AU - Peterson, Justin

AU - McDonagh, Paul F.

PY - 2010

Y1 - 2010

N2 - Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P =.01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P =.1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P <.05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P <.05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.

AB - Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P =.01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P =.1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P <.05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P <.05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.

UR - http://www.scopus.com/inward/record.url?scp=79953269508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953269508&partnerID=8YFLogxK

U2 - 10.1155/2010/820876

DO - 10.1155/2010/820876

M3 - Article

C2 - 21318184

AN - SCOPUS:79953269508

SN - 1687-8337

VL - 2010

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

M1 - 820876

ER -

Effect of glucose or fat challenge on aspirin resistance in diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this